糖尿病视网膜病变(diabetic retinopathy,DR)是糖尿病患者常见和严重的并发症之一,是糖尿病患者视力损害的最主要原因。随着对糖尿病发病机制的深入研究,近年来多种药物用于DR的防治并取得了一定疗效,包括糖皮质激素、血管生长因子抑制剂、蛋白激酶C(protein kinase C,PKC)抑制剂、肾素-血管紧张素受体拮抗剂坎地沙坦及非诺贝特等,我们就近年来药物治疗DR的现状及进展作一综述。

Diabetic retinopathy(DR)is one of the common and severe complications in patients with diabetes,which is the leading cause of impairment of vision in diabetic patients.In recent years,following advanced research of diabetic etiopathogenesis,further advances in pharmacotherapy have shown promise in the treatment of DR,including corticosteroids,vascular endothelial growth factor(VEGF) inhibitors,protein kinase C(PKC) inhibitors,renin-angiotensin system blockers Candesartan and fenofibrate.This review will focus on DR present and potential future pharmacologic treatments.